title: Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice.
abstract: Influenza viruses remain a major threat to global health due to their ability to undergo change through antigenic drift and antigenic shift. We postulated that avian IgY antibodies represent a low-cost, effective, and well-tolerated approach that can easily be scaled up to produce enormous quantities of protective antibodies. These IgY antibodies can be administered passively in humans (orally and intranasally) and can be used quickly and safely to help in the fight against an influenza pandemic. In this study, we raised IgY antibodies against H1N1, H3N2, and H5N1 influenza viruses. We demonstrated that, using whole inactivated viruses alone and in combination to immunize hens, we were able to induce a high level of anti-influenza virus IgY in the sera and eggs, which lasted for at least 2 months after two immunizations. Furthermore, we found that by use of in vitro assays to test for the ability of IgY to inhibit hemagglutination (HI test) and virus infectivity (serum neutralization test), IgYs inhibited the homologous as well as in some cases heterologous clades and strains of viruses. Using an in vivo mouse model system, we found that, when administered intranasally 1 h prior to infection, IgY to H5N1 protected 100% of the mice against lethal challenge with H5N1. Of particular interest was the finding that IgY to H5N1 cross-protected against A/Puerto Rico/8/34 (H1N1) both in vitro and in vivo. Based on our results, we conclude that anti-influenza virus IgY can be used to help prevent influenza virus infection.
authors: iThree Institute, University of Technology Sydney, Broadway, Sydney, NSE 2007, Australia. Michael.Wallach@uts.edu.au
authors: Michael G
authors: MG
authors: Wallach
authors: Richard J
authors: RJ
authors: Webby
authors: Fakhrul
authors: F
authors: Islam
authors: Stephen
authors: S
authors: Walkden-Brown
authors: Eva
authors: E
authors: Emmoth
authors: Ricardo
authors: R
authors: Feinstein
authors: Kjell-Olov
authors: KO
authors: Gronvik
references: PLoS One. 2008;3(12):e3942
references: 19079604
references: N Engl J Med. 2005 Dec 22;353(25):2667-72
references: 16371632
references: Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12915-20
references: 16118277
references: Nat Struct Mol Biol. 2009 Mar;16(3):265-73
references: 19234466
references: Ups J Med Sci. 1999;104(3):179-89
references: 10680951
references: Biochem Biophys Res Commun. 2009 Sep 11;387(1):180-5
references: 19580789
references: PLoS One. 2010 Apr 13;5(4):e10152
references: 20405007
references: Clin Pharmacokinet. 1997 Apr;32(4):313-23
references: 9113439
references: Emerg Infect Dis. 2006 Apr;12(4):569-74
references: 16704803
references: PLoS Med. 2007 May;4(5):e178
references: 17535101
references: Clin Diagn Lab Immunol. 2002 Sep;9(5):1061-6
references: 12204960
references: Vaccine. 1995 Mar;13(4):347-54
references: 7793129
references: Respir Res. 2006 Mar 23;7:43
references: 16553963
references: J Virol. 1993 May;67(5):2552-8
references: 7682624
references: Pediatr Pulmonol. 2003 Jun;35(6):433-40
references: 12746939